Progenics pharmaceuticals inc (PGNX)
Income statement / Yearly
Dec'19Dec'18Dec'17Dec'16Dec'15Dec'14Dec'13Dec'12Dec'11Dec'10Dec'09
Revenues:
Revenue

34,986

15,622

11,698

69,429

8,676

44,377

7,862

14,048

84,796

7,952

-

Research grants

-

-

-

-

-

-

275

488

4,810

4,573

1,968

Other revenue

-

-

-

-

113

80

69

72

176

140

256

Operating expenses:
Cost of goods sold

3,168

-

-

-

-

-

-

-

-

-

-

Research and development

49,223

35,147

42,589

37,569

28,196

28,592

34,582

31,332

53,183

50,640

49,798

Selling, general and administrative

47,838

29,431

24,909

23,356

18,184

15,489

15,541

15,214

18,248

22,832

25,106

Intangible impairment charge

-

23,200

-

-

-

-

-

-

-

-

-

License fees - research and development

-

-

-

-

-

-

-

1,170

578

1,270

1,058

Total revenues

-

-

-

-

-

-

-

-

-

-

48,947

Royalty expense

-

-

-

-

-

-

-

499

405

241

237

Depreciation and amortization

-

-

-

-

-

-

-

1,324

2,066

2,853

5,078

Intangible impairment charges

-

-

-

-

-

2,676

919

0

-

-

-

Change in contingent consideration liability

916

-5,800

2,600

-4,600

1,600

1,500

-200

0

-

-

-

Total operating expenses

101,145

81,978

70,098

56,325

47,980

48,257

50,842

49,539

74,480

77,836

81,277

Other operating income

-

-

-

-

-

7,250

0

0

-

-

-

Operating loss

-66,159

-66,356

-58,400

13,104

-39,304

3,370

-42,980

-35,491

10,316

-69,884

-32,330

Other (expense) income:
Interest (expense) income and other income, net

-2,376

-2,933

-4,285

-527

52

51

-

-

-

-

-

Other expense, net

-

-

-

-

-

0

-

-

-

-

-

Interest income

-

-

-

-

-

-

46

60

65

64

1,481

Gain on sale of marketable securities

-

-

-

-

-

-

-

-

-

-

237

Total other (expense) income

-2,376

-2,933

-4,285

-527

52

51

46

60

65

64

1,718

Loss before income tax (expense) benefit

-68,535

-69,289

-62,685

12,577

-39,252

3,421

-42,934

-35,431

10,381

-69,820

-30,612

Income tax (expense) benefit

17

-1,632

-11,672

1,844

-133

-989

-362

0

0

-95

0

Net (loss) income

-

-

-

10,733

-39,119

4,410

-42,572

-

-

-

-

Net loss attributable to noncontrolling interests

-

-

-

-73

-7

0

0

-

-

-

-

Net loss

-68,552

-67,657

-51,013

10,806

-39,112

4,410

-42,572

-35,431

10,381

-69,725

-30,612

Net (loss) income per share attributable to Progenics - basic (in dollars per share)

-

-

-

0.15

-0.56

0.06

-0.76

-1.02

0.31

-2.14

-0.98

Weighted-average shares - basic (in shares)

-

-

-

70,003

-

68,185

55,798

34,754

33,375

32,590

-

Net (loss) income per share attributable to Progenics - diluted (in dollars per share)

-

-

-

0.15

-0.56

0.06

-0.76

-1.02

0.31

-2.14

-0.98

Weighted-average shares - diluted (in shares)

-

-

-

70,155

69,716

68,243

55,798

34,754

33,494

32,590

31,219

Net loss per share - basic and diluted (in dollars per share)

-0.80

-0.87

-0.73

-

-

-

-

-

-

-

-

Weighted-average shares - basic and diluted (in shares)

85,607

77,890

70,284

-

69,716

-

-

-

-

-

31,219

Product [Member]
Revenue

1,559

-

-

-

-

-

-

-

-

-

-

Royalty [Member]
Revenue

16,970

14,908

10,965

10,295

6,608

3,101

5,923

4,963

3,046

1,826

2,372

License and Other [Member]
Revenue

16,457

714

733

-

-

-

-

-

-

-

-

Product and Service, Other [Member]
Revenue

-

-

-

59,134

1,955

41,196

1,595

8,525

76,764

1,413

44,351